Acer Therapeutics Cost of Revenue 2011-2026 | ACER

Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.

What is included in the cost of revenue

Cost Category	Examples
Production Costs	Materials, wages of production staff, depreciation of equipment
Service and Support	Customer service, user support, technical assistance
Delivery and Logistics	Packaging, delivery of goods to customers
Hosting and Infrastructure	Servers, cloud platforms (especially for IT and SaaS companies)
Content and Licenses	License purchases, production royalties (e.g., in streaming services)

Importance of the Metric

Helps to understand how costly the revenue-generating process is.
A high cost of revenue may indicate:
Poor cost control
Low operational efficiency
A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.

Quarterly Cost of Revenue Acer Therapeutics

2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
83.8 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
83.8 K	83.8 K	83.8 K

Cost of Revenue of other stocks in the Biotechnology industry

Issuer	Cost of Revenue	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	32.2 M	-	2.43 %	$ 254 M	Germany
AbbVie ABBV	18.2 B	$ 232.08	3.29 %	$ 411 B	USA
ACADIA Pharmaceuticals ACAD	81.8 M	$ 24.56	-0.32 %	$ 4.07 B	USA
I-Mab IMAB	27.2 M	-	-	$ 866 M	China
AgeX Therapeutics AGE	40 K	-	-10.17 %	$ 12.2 K	USA
Aclaris Therapeutics ACRS	2.09 M	$ 2.87	-8.31 %	$ 352 M	USA
ADC Therapeutics SA ADCT	1.39 M	$ 4.1	-0.73 %	$ 105 M	Schweiz
ADMA Biologics ADMA	217 M	$ 15.57	2.57 %	$ 3.71 B	USA
Adaptive Biotechnologies Corporation ADPT	71.4 M	$ 16.02	-2.67 %	$ 2.43 B	USA
ADiTx Therapeutics ADTX	627 K	$ 0.46	-4.63 %	$ 6.06 K	USA
Midatech Pharma plc MTP	926 K	-	-18.52 %	$ 27.3 M	Britain
Agenus AGEN	3.11 M	$ 3.33	-0.89 %	$ 1.19 M	USA
Agios Pharmaceuticals AGIO	6.34 M	$ 30.23	0.83 %	$ 1.75 B	USA
AIM ImmunoTech AIM	1.25 M	$ 0.91	-8.59 %	$ 43.8 M	USA
Akebia Therapeutics AKBA	39.5 M	$ 1.31	-0.76 %	$ 337 M	USA
Acorda Therapeutics ACOR	15.3 M	-	-24.86 %	$ 820 K	USA
Acasti Pharma ACST	76 K	-	4.01 %	$ 150 M	Canada
Alector ALEC	51.8 M	$ 2.43	-5.08 %	$ 250 M	USA
Adverum Biotechnologies ADVM	100 K	-	-	$ 86.2 M	USA
Alkermes plc ALKS	196 M	$ 30.1	-2.05 %	$ 4.96 B	Irlanda
AIkido Pharma AIKI	9 K	-	1.93 %	$ 17.4 M	USA
Alnylam Pharmaceuticals ALNY	677 M	$ 332.92	0.51 %	$ 43.6 B	USA
Albireo Pharma ALBO	1.36 M	-	-0.23 %	$ 916 M	USA
Amgen AMGN	12 B	$ 388.16	2.33 %	$ 209 B	USA